Wednesday, July 8, 2026

biotech · Type 1 Diabetes Mellitus · Dehydration · HALO

HALOZYME THERAPEUTICS

HALOZYME THERAPEUTICS is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker HALO. Primary therapeutic focus areas include Type 1 Diabetes Mellitus, Dehydration, Pancreatic Ductal Adeno

12390 El Camino Real, San Diego, California 92130, US HQ
2021 Founded
530 Employees
Public company Type
HALO · NYSE Ticker
Company details
Status
Public
HQ
12390 El Camino Real, San Diego, California 92130, US
Founded
2021
Employees
530
Programs
45
Drugs
33
Patents
70
Clinical program

Testosterone enanthate

Phase 3 · other · Hypogonadism, Male

Testosterone enanthate for Hypogonadism, Male is a Phase 3 program (other) at HALOZYME THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).

Internal code ATRS QST-19-007

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
HALOZYME THERAPEUTICS, INC.
Phase
Phase 3
Modality
other
Indication
Hypogonadism, Male
Status
active
Trials
1